Levosimendan for patients with heart failure undergoing major oncological surgery: A randomised blinded pilot study

Conclusion: In patients with low EF <35% and CHF, administration of levosimendan for 24 hours before major abdominal oncologic surgeries may reduce the risk of hypotension and decompensated heart failure and may improve cardiac function.

Source: Indian Journal of Anaesthesia - December 10, 2019 Category: Anesthesiology Authors: Ehab H Shaker Khaled Hussein Ehab M Reyad Source Type: research